Simple Blood Test Aids Risk Assessment for Approximately 14 Million Eligible Patients in the United States Diabetic Kidney Disease is the Leading Cause of End Stage Kidney Disease in the United States LONDON and SALT LAKE CITY, June 29, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX)
Four new data presentations, including late breaking clinical study data, underscores the value of KidneyIntelX testing in helping slow progression of chronic kidney disease in type 2 diabetes patients LONDON and SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE:
RNS Number : 7716C Renalytix PLC 15 June 2023 Renalytix plc ("Renalytix" or the "Company") KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences Four new data presentations, including late breaking clinical study data,
LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today
RNS Number : 1817C Renalytix PLC 09 June 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023 LONDON and SALT LAKE CITY , June 9, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in
RNS Number : 1562C Renalytix PLC 08 June 2023 Renalytix plc ("Renalytix" or the "Company") Result of General Meeting LONDON and SALT LAKE CITY , June 8, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that at the General Meeting (" GM ") held earlier today all resolutions
LONDON and SALT LAKE CITY, June 05, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter fiscal year 2023 financial results on Friday, June 9, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the
RNS Number : 5700B Renalytix PLC 05 June 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9 LONDON and SALT LAKE CITY , June 5, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter
Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage LONDON and CHICAGO, May 25, 2023 (GLOBE NEWSWIRE) -- Renalytix (NASDAQ: RNLX) (LSE: RENX) , the first company to develop and commercialize an
RNS Number : 5773A Renalytix PLC 25 May 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes Model expected to accelerate deployment of
